NCCN 2025 Lung Cancer Congress

November 7, 2025

The NCCN 2025 Lung Cancer Congress is designed to provide the interprofessional oncology care team with practical guidance on the latest updates to the NCCN Guidelines, novel and emerging therapies, recent clinical research, and strategies to align new developments with current standards of care. This activity aims to support the implementation of evidence-based, team-driven approaches to improve outcomes for patients with lung cancer, particularly in community-based practice.

Target Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, pharmacists, physician associates, and other relevant health care professionals who treat patients with lung cancer.

Learning Objectives

The goal of the program is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:

  • Apply the current standards of oncology care and key updates in the NCCN Guidelines to optimize the management of patients with lung cancer.
  • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with lung cancer.
  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with lung cancer.

Click here to view the learning objectives for each individual session.

Additional information
AttachmentSize
PDF icon Program Information (agenda, disclosures, biographies)1.41 MB
PDF icon SCLC: Practical Strategies for Primary and Subsequent Systemic Therapy4.88 MB
PDF icon The Role of Radiation Therapy in Small Cell Lung Cancer3.3 MB
PDF icon Systemic Therapy in Early-Stage, Wild-Type NSCLC2.88 MB
PDF icon Targeted Therapy for Early-Stage, EGFR- and ALK-Positive NSCLC3.18 MB
PDF icon Multidisciplinary Coordination and Treatment Sequencing in NSCLC Care3.08 MB
PDF icon Biomarker Testing in NSCLC: What’s New and What’s Next1.85 MB
PDF icon Managing EGFR-Positive NSCLC Across the Treatment Spectrum3.57 MB
PDF icon Practical Integration of Radiation Therapy in Metastatic NSCLC5.37 MB
PDF icon KRAS Mutations in NSCLC: Current Landscape and Evolving Therapies5.14 MB
PDF icon Rare Targets and Novel Therapies in NSCLC5.77 MB
PDF icon Toxicity and Symptom Management Related to Oral Agents and TKIs1.47 MB
PDF icon Lab Monitoring Made Simple: A Practical Guide for the Oncology Care Team1.7 MB
Supporters: 

This activity is supported by educational grants from:

  • Exact Sciences
  • Genentech, a member of the Roche Group
  • Johnson & Johnson

This activity is supported by independent medical education grants from: 

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.
Course summary
Available credit: 
  • 6.75 AAPA Category 1 CME credit
  • 6.75 ACPE contact hours
  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 ANCC contact hours
  • 6.75 CCM clock hours
  • 6.75 Participation
  • 6.75 NCRA CEIP Hours
    The NCCN 2025 Lung Cancer Congress program supports 6.75 CEIP hours of which 6.75 hours meet the Category A requirement. This program has been assigned the following event number: 2025-274IP.
    • 6.75 Category A (IP)
  • 6.75 NCRA CE hours
    • 6.75 Category A
Course opens: 
11/06/2025
Course expires: 
02/22/2026
Event starts: 
11/07/2025 - 10:00am EST
Event ends: 
11/07/2025 - 5:30pm EST
Cost:
$0.00
Add to calendar: 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Congress Planning Committee

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Michael Seidman, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Charu Aggarwal, MD, MPH (Presenting Faculty) 
AbbVie, Inc.: Consulting Fee
Arcus Biosciences: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Boehringer Ingelheim GmbH: Consulting Fee
Daiichi Sankyo, Inc./AstraZeneca Pharmaceuticals LP: Consulting Fee 
Gilead Sciences, Inc.: Consulting Fee
Loxo@Lilly: Consulting Fee
Novocure: Consulting Fee
Merck Sharp & Dohme: Consulting Fee
Pfizer Inc.: Consulting Fee
Sanofi/Regeneron: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Hossein Borghaei, DO, MS (Presenting Faculty)
AbbVie, Inc.: Consulting Fee; Scientific Advisor
Amgen Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Astellas Pharma US, Inc.: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
Axiom: Consulting Fee; Scientific Advisor
Bayer HealthCare: Consulting Fee; Scientific Advisor
BeiGene: Consulting Fee; Scientific Advisor
BerGenBio: Consulting Fee; Scientific Advisor
BioNTech: Consulting Fee; Scientific Advisor
Boehringer Ingelheim GmbH: Consulting Fee; Scientific Advisor
Bristol Myers Squibb: Consulting Fee; Grant/Research Support; Scientific Advisor
Daiichi- Sankyo Co.: Consulting Fee; Honoraria; Scientific Advisor
Eli Lilly and Company: Consulting Fee; Grant/Research Support; Scientific Advisor
EMD Serono: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Scientific Advisor
Genmab: Consulting Fee; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
Grid Therapeutics: Consulting Fee; Scientific Advisor
Guardant Health: Consulting Fee; Scientific Advisor
Incyte Corporation: Scientific Advisor
Inspirna (formerly RGENIX): Equity Interest/Stock Options; Scientific Advisor
IO Bioetech: Consulting Fee; Scientific Advisor
iTeos Therapeutics: Consulting Fee; Scientific Advisor
Janssen Pharmaceutica Products, LP: Consulting Fee; Honoraria; Scientific Advisor
Jazz Pharmaceuticals Inc.: Consulting Fee; Honoraria; Scientific Advisor
Merck & Co., Inc.: Consulting Fee; Scientific Advisor
Mirati Therapeutics, Inc.: Consulting Fee; Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee; Scientific Advisor
Novocure: Consulting Fee; Scientific Advisor
Natera: Consulting Fee; Scientific Advisor
Oncocyte: Consulting Fee; Scientific Advisor
PharmaMar: Consulting Fee; Scientific Advisor
Pfizer Inc.: Consulting Fee; Honoraria; Scientific Advisor
Puma Biotechnology: Consulting Fee; Scientific Advisor
RAPT Therapeutics Consulting Fee; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Consulting Fee; Honoraria; Scientific Advisor
Servier: Scientific Advisor
Sonnet BioTherapeutics, Inc.: Equity Interest/Stock Options; Scientific Advisor
SpringWorks Therapeutics: Scientific Advisor
Summit Therapeutics Consulting Fee; Scientific Advisor
SystImmune, Inc.: Consulting Fee; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor

Gregory J. Riely, MD, PhD (Congress Chair and Moderator)
Amgen Inc.: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

Presenting Faculty

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Sophia Gilardone, PharmD, BCOP 
Ana Lucia Ruano Mendez, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Aakash Desai, MD, MPH
AbbVie, Inc.: Honoraria; Scientific Advisor
Amgen Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Bayer HealthCare: Honoraria; Scientific Advisor
Bristol Myers Squibb: Honoraria; Scientific Advisor
Eli Lilly and Company: Honoraria: Scientific Advisor
Foundation Medicine, Inc.: Honoraria; Scientific Advisor
Janssen Pharmaceutica Products, LP: Honoraria; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Honoraria; Scientific Advisor

Jonathan E. Dowell, MD
Genentech, Inc.: Honoraria
Nuvation Bio, Inc.: Honoraria
Pfizer Inc.: Honoraria

Christine L. Hann, MD, PhD 
AbbVie, Inc.: Consulting Fee
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Daiichi- Sankyo Co.: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee
 
Aditya Juloori, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
EMD Serono: Consulting Fee
GSK: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Consulting Fee

Billy W. Loo, MD, PhD
BeiGene: Scientific Advisor
Mevion Medical Systems: Honoraria

Melina E. Marmarelis, MD, MSCE 
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Bayer HealthCare: Consulting Fee
Boehringer Ingelheim GmbH: Consulting Fee
Bristol Myers Squibb: Consulting Fee
Daiichi- Sankyo Co.: Consulting Fee
Eli Lilly and Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee; Grant/Research Support
Johnson & Johnson: Equity Interest/Stock Options
Merck & Co., Inc.: Equity Interest/Stock Options; Grant/Research Support
NEUVOGEN, Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
Thermo Fisher Scientific Inc.: Honoraria

Dawn Owen, MD, PhD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Varian Medical Systems, Inc.: Grant/Research Support

Dwight H. Owen, MD, MS
AbbVie, Inc.: Grant/Research Support
Amgen Inc.: Non-royalty Payments
AstraZeneca Pharmaceuticals LP: Non-royalty Payments
Bristol Myers Squibb: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Non-royalty Payments
Merck & Co., Inc.: Grant/Research Support
Onc.AI: Grant/Research Support
Palobiofarma LLC: Grant/Research Support
Pfizer Inc.: Grant/Research Support

Beth Sandy, MSN, CRNP
AbbVie, Inc.: Consulting Fee
Amgen Inc.: Product/Speakers Bureau
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Catalyst Pharmaceuticals, Inc.: Consulting Fee
Eli Lilly and Company: Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fee; Product/Speakers Bureau
Jazz Pharmaceuticals Inc.: Product/Speakers Bureau
Merck & Co., Inc.: Product/Speakers Bureau
Pfizer Inc.: Consulting Fee

Jane Yanagawa, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 6.75 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 6.75 contact hours (0.675 CEUs) of continuing education credit. UAN: JA4008196-0000-25-110-L01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Continuing Certification (CC)

This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn up to 6.75 Lifelong Learning (Part II) credits. Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Surgery Continuous Certification (CC)


Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Thoracic Surgery (CC)
Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Thoracic Surgery’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.

American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) MOC Initiative to create a wide array of Maintenance of Certification (“MOC”) Activities through the ABMS MOC Directory, the NCCN 2025 Lung Cancer Congress has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

MOC Part II CME Activity
Radiology

Case Managers

This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 6.75 CE contact hours. Activity code: C00065090 Approval Number: 250003386

Oncology Data Specialists (Virtual Attendance)

The NCCN 2025 Lung Cancer Congress program supports 6.75 CE hours of which 6.75 hours meet the Category A requirement. This program has been assigned the following event number: 2025-274.

Oncology Data Specialists (In-Person Attendance)

The NCCN 2025 Lung Cancer Congress program supports 6.75 CEIP hours of which 6.75 hours meet the Category A requirement. This program has been assigned the following event number: 2025-274IP.

 

Permission to Upload Credits
For ABIM, ABPath, ABS, and ABTS MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.

Available Credit

  • 6.75 AAPA Category 1 CME credit
  • 6.75 ACPE contact hours
  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 ANCC contact hours
  • 6.75 CCM clock hours
  • 6.75 Participation
  • 6.75 NCRA CEIP Hours
    The NCCN 2025 Lung Cancer Congress program supports 6.75 CEIP hours of which 6.75 hours meet the Category A requirement. This program has been assigned the following event number: 2025-274IP.
    • 6.75 Category A (IP)
  • 6.75 NCRA CE hours
    • 6.75 Category A

Price

Cost:
$0.00
Please login or register to take this course.

 

Please log in with the email address you used for event registration.

Click the Take Course button to start the credit claiming process.

CE/MOC credit should be claimed for the congress as a whole, not session by session. You may claim credit for the congress only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Recordings will be available in the online platform by November 26.)

Pharmacists: you must complete all requirements for credit by December 17, 2025.

 

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing